Cystatin C-based GFR formulas can provide an accurate estimation of nuclear GFR in the pediatric population, including transplant recipients [85] and hence should overcome some of the shortcomings of SCr as a biomarker for AKI in liver disease. This evidence concerns the gene CST3 and acute kidney injury.